Elsevier

Biochemical Pharmacology

Volume 51, Issue 7, 12 April 1996, Pages 949-956
Biochemical Pharmacology

Research paper
Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

https://doi.org/10.1016/0006-2952(96)00053-6Get rights and content

Abstract

Phosphodiesterase 4 (PDE4) inhibitors are novel anti-inflammatory compounds. Unfortunately, the archetypal PDE4 inhibitor rolipram produces central nervous system and gastrointestinal side-effects. To exploit these agents, we need to identify PDE4 inhibitors that retain the anti-inflammatory activity with a reduced potential to elicit unwanted side-effects. PDE4 possesses both cyclic AMP catalytic activity that is inhibitable by rolipram and a high affinity binding site for rolipram. The function of this high affinity rolipram binding site is unclear; however, certain pharmacological effects of PDE4 inhibitors are associated with competition for this site. Since PDE4 inhibitors suppress both monocyte and neutrophil activation, the present experiments were carried out to establish a correlation between suppression of monocyte activation [tumor necrosis factor alpha (TNFa) formation] or suppression of neutrophil activation (degranulation) with inhibition of either PDE4 catalytic activity or [3H]rolipram binding. Suppression of TNFa formation demonstrated a strong correlation with inhibition of PDE4 catalytic activity (r = 0.87; P < 0.01; Spearman's Rho = 0.79, P < 0.05), whereas there was no correlation with inhibition of [H]rolipram binding (r = 0.21, P > 0.5; Spearman's Rho = 0.16, P > 0.5). Suppression of neutrophil degranulation was not associated with inhibition of PDE4 catalytic activity (r = 0.25, P > 0.4; Spearman's Rho = 0.33, P > 0.2), but was associated with inhibition of [3H]rolipram binding (r = 0.68, P < 0.05; Spearman's Rho = 0.6, P = 0.06). These results indicate that anti-inflammatory effects of PDE4 inhibitors can be associated with either inhibition of PDE4 catalytic activity or high affinity rolipram binding.

References (34)

  • S Nourshargh et al.

    Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors

    Eur J Pharmacol

    (1986)
  • HH Schneider et al.

    Stereospecific binding of the antidepressant rolipram to brain protein structures

    Eur J Pharmacol

    (1986)
  • R Obernolte et al.

    The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family

    Gene

    (1993)
  • P Engels et al.

    Expression and regulation of human rat phosphodiesterase type IV isogenes

    FEBS Lett

    (1994)
  • PT Peachell et al.

    Preliminary identification and role of phosphodiesterase isozymes in human basophils

    J Immunol

    (1992)
  • C Schudt et al.

    Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

    Naunyn Schmiedebergs Arch Pharmacol

    (1991)
  • R Horowski et al.

    Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports

    Curr Therap Res

    (1985)
  • Cited by (0)

    View full text